Stockwinners Market Radar for October 17, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:43 EDT Takeda's topline results of ph3 trial of Alofisel did not meet primary endpoint - The company states: "Takeda announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel, or darvadstrocel, for the treatment of complex Crohn's Perianal Fistulas, did not meet its primary endpoint of combined remission at 24 weeks, based on topline data. The safety profile for darvadstrocel was consistent with prior studies and there were no new safety signals identified. Alofisel is approved in the European Union, Israel, Switzerland, Serbia, United Kingdom and Japan based on positive data from the previously completed ADMIRE-CD study. The approval in Japan is also based on positive data from the Japanese study, Darvadstrocel-3002. In addition, approximately 800 patients have been enrolled in INSPIRE, an ongoing, observational study of the real-world effectiveness and safety of Alofisel in patients with complex CPF. Takeda is continuing to assess the financial impacts of the study results, including impairment loss for intangible assets, on the fiscal quarter ended September 30, 2023. Any revisions to the consolidated forecast for the fiscal year ending March 31, 2024 (FY2023) will be announced during Takeda's second quarter earnings call, scheduled for October 26, 2023."

19:23 EDT Ardelyx announces FDA approves XPHOZAH in adults with CKD - Ardelyx "announced that the U.S. Food and Drug Administration has approved XPHOZAH, or tenapanor, the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. XPHOZAH is a single tablet taken twice daily that offers a first-in-class mechanism of action that blocks phosphate absorption through its primary pathway. FDA approval of XPHOZAH is based on a comprehensive development program, including a diverse population of more than 1,000 patients in three Phase 3 clinical trials evaluating the efficacy and safety of XPHOZAH, as monotherapy and in combination with phosphate binder therapy, all of which met their primary and key secondary endpoints. Data from the three clinical trials demonstrated that XPHOZAH significantly reduced elevated serum phosphorus in patients receiving maintenance hemodialysis. Diarrhea, which occurred in 43 to 53 percent of patients, was the only adverse reaction reported in at least five percent of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in the XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in five percent of XPHOZAH-treated patients in these trials. Ardelyx also completed two open-label clinical trials to evaluate different options for integrating XPHOZAH into clinical practice."

18:32 EDT Warrantee receives non-compliance letter from Nasdaq - Warrantee announced that the Company received a letter from the Listings Qualifications Department of the Nasdaq Stock Market on October 13, notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550 for continued listing on Nasdaq. This press release is issued pursuant to Nasdaq Listing Rule 5810, which requires prompt disclosure upon the receipt of a deficiency notification. The Company intends to monitor the closing bid price of its ADSs and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse share split of its outstanding ADSs, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.

17:51 EDT Talaris Therapeutics announces 1-for-10 reverse stock split - Talaris announced that it will effect a 1-for-10 reverse stock split of its common stock that will be effective on Thursday, October 19, 2023, prior to the closing of the Merger. At the special meeting of stockholders, the holders of a majority of Talaris' outstanding shares of common stock also approved the reverse stock split and gave Talaris' board of directors discretionary authority to select a ratio for the split ranging from 1-for-10 to 1-for-14. The combined company's common stock is expected to begin trading on Nasdaq on a split-adjusted basis on Friday, October 20, 2023. The new CUSIP number for the combined company's common stock following the Merger and the reverse stock split is 89157D 105.

17:50 EDT Talaris Therapeutics shareholders approve merger with Tourmaline Bio - Talaris Therapeutics announced the results of the special meeting of its stockholders held on October 17, 2023. At the special meeting, Talaris' stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Talaris' common stock to the stockholders of Tourmaline Bio, pursuant to the terms of the Agreement and Plan of Merger, dated as of June 22, 2023, pursuant to which a direct wholly owned subsidiary of Talaris will merge with and into Tourmaline, with Tourmaline surviving the merger as a direct wholly owned subsidiary of Talaris. The closing of the Merger is anticipated to take place on or around Thursday, October 19, 2023. Following the closing of the Merger, the combined company plans to change its name from Talaris Therapeutics to Tourmaline Bio, trade on The Nasdaq Global Market under the ticker symbol "TRML" and will be led by Tourmaline's existing management team. The combined company will focus on Tourmaline's mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases.

17:49 EDT BHP reports Q1 copper production up 11% year-over-year - "First quarter operational performance was highlighted by a 11% uplift in copper production from the previous year," the company said. "After completing a typically busy quarter of planned maintenance particularly at our Australian assets, we are on track to achieve full year production and unit cost guidance. BMA in particular was impacted by planned maintenance, an extended longwall move and low opening inventory following drawdowns in the prior year. Jansen Stage 1 in Canada is approximately one-third complete after a productive summer. In South Australia, we saw strong operational performance in the first full quarter of production for the new province, as we bring our copper assets together and progress further exploration drilling."

17:33 EDT Gogo 5G selected by AirSprint Private Aviation - Gogo Business Aviation announced AirSprint Private Aviation, a leading Canadian fractional operator, will begin upgrading its Cessna Citation CJ3+ and Embraer aircraft to Gogo 5G-making it Gogo's first Canadian fleet customer. Gogo 5G is expected to deliver speeds five to 10 times faster than current speeds, at approximately 25 Mbps on average, and 75-80 Mbps at its peak. Expansion of the Gogo 5G network in Canada will add significantly more time for inflight connectivity for operators flying in or through the country. Gogo is the only air-to-ground (ATG) company in business aviation with coverage in Canada and Alaska. The agreement also includes options for AirSprint to upgrade its midsize aircraft with Gogo Galileo HDX, Gogo's Low Earth Orbit global broadband solution, expected to launch in the second half of 2024.

17:28 EDT United Airlines sees total mainline aircraft 945 at year end 2023 - Sees total regional aircraft 413 at year end 2023.

17:25 EDT Vicor jumps 4% to $55.72 after inclusion in S&P 600

17:24 EDT Floor & Decor jumps 7% to $90.74 after inclusion in S&P 400

17:19 EDT Vicor to replace Circor in S&P 600 at open on 10/20 - KKR & Co. (KKR) is acquiring CIRCOR International (CIR) in a transaction expected to close October 18.

17:15 EDT SSR Mining to sell Sunrise Lake Property to Honey Badger Silver - SSR Mining announced that it has entered into a definitive agreement to sell its Sunrise Lake Property to Honey Badger Silver in exchange for a 4.0% net smelter return royalty on the Property. Under the terms of the agreement, at any time until commencement of construction activities, 2.0% of the NSR royalty can be repurchased by Honey Badger for total consideration of $10M. Sunrise Lake is an early-stage, greenfield exploration property located in the Northwest Territories, 130 kilometers northeast of Yellowknife. The Property hosts silver-gold and base metal mineralization outlined by 21,774 meters of historical surface diamond drilling completed between discovery in 1987 and 1998. Exploration activities completed on the Property to-date have focused on silver-lead-zinc volcanogenic massive sulfide mineralization.

17:07 EDT InterCure provides update regarding security situation in Israel - InterCure addressed the status of the security situation in the State of Israel, and its impact on the Company and its employees. The company said, "On October 7, 2023, Hamas terrorists infiltrated Israel's southern border (the "Israeli Southern Border") from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel's border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. Following the attack, Israel's security cabinet declared war against Hamas and a military campaign against these terrorist organizations. As a Company that chose to establish its main facility in Kibbutz Nir Oz (the "Southern Israel Site"), approximately 2 kilometers from the Gaza border, we stand united with the Israeli villages and towns bordering the Gaza Strip, all the victims of the terrorist attack, the citizens and the defense forces of our country. We seek to strengthen and embrace all those who need assistance. Together, we will win. Despite the numerous challenges, the Company's management, cannabis trading houses, and pharmacies are working diligently to provide the required service to patients, and meet the growing demand for the Company's products, especially during this difficult period. The Southern Israel Site in Kibbutz Nir Oz, one of the most advanced and largest facilities in Israel and outside North America, encompasses the largest genetic bank and inventory in Israel. Since the beginning of the war, the Southern Israel Site facility in Nir Oz has been designated by the Israeli authorities as a closed military area. At this point, the Company is unable to assess the extent of the damage to the Southern Israel Site, and the scope of the rehabilitation that will be required. All of the Company's remaining facilities, in Israel and abroad, are functioning normally, and have been asked to ramp up production. The Company estimates in high certainty that it will be entitled for compensation from the Israeli Government for the damages suffered. During the COVID-19 pandemic, the Company's facilities, including the Southern Israel Site in Nir-Oz, were recognized as an "essential enterprise" by the Israeli government.The Company has received substantial offers to supply its inventories and to grow its genetics from various local and international strategic partners. At this point, the duration of the war, and its direct and indirect damages are highly uncertain. While the Company is estimated in high certainty that the Israeli government will compensate the Company for damages that were caused by the terrorist attack and the war, the Company is currently unable to estimate the impact on its financial results. As the largest and leading medical cannabis company in Israel, InterCure has decided to support and supply the communities in the Israeli Southern Border, as well as the survivors from the terrorist attack, with its line of products, free of charge, to ease their pain and provide relief for various medical conditions, including pain relief and trauma treatment. The Company is working closely with the Ministry of Health of Israel to promote special trauma treatment programs..."

17:02 EDT Tenable OT Security selected by Chubu Electric Power Grid - Tenable announced that Chubu Electric Power Grid has chosen Tenable OT Security to ensure the supply of power in the Chubu region is not disrupted by cyberattacks and natural disasters. Amidst the rising complexity of cyberattacks on critical infrastructure and the emergence of insider threats, Chubu Electric Power Grid recognized that preventive cyber risk hinges upon comprehensive knowledge of asset distribution and potential vulnerabilities.

16:53 EDT J.M. Smucker announces agreement to sell condiments brands to TreeHouse Foods - The J.M. Smucker (SJM) announced it has entered into a definitive agreement to sell its Bick's pickles, Habitant pickled beets, Woodman's horseradish and McLarens pickled onions brands to TreeHouse Foods (THS), a leading private label food and beverage manufacturer in North America. The all-cash transaction is valued at approximately $20M, subject to a working capital adjustment. The brands included in the transaction generated net sales of approximately $60M for the Company's fiscal year ended April 30 which were reported in its International and Away From Home results. The Company expects the impact of the divestiture to be immaterial to its adjusted earnings per share on a full-year basis. The Company will provide additional information about the transaction's impact on its fiscal year 2024 outlook during the next quarterly earnings call. The transaction is anticipated to close in the Q3 of the Company's current fiscal year ending April 30, 2024, subject to customary closing conditions.

16:33 EDT Fulton Financial reports Q3 net interest margin 3.40% vs. 3.54% last year - Reports Q3 net charge-offs 0.10% vs. 0.01% last year and Q3 provision for credit losses of $9.9M vs. $19.0M last year.

16:32 EDT Mirum says FDA extends review of sNDA for LIVMARLI - Mirum Pharmaceuticals announced that the U.S. Food and Drug Administration has extended the review of the Supplemental New Drug Application for LIVMARLI oral solution for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis. The new Prescription Drug User Fee Act date is March 13, 2024. The FDA extended the PDUFA date to allow time for a full review of a submission provided in response to an FDA information request, which the FDA deemed a major amendment. The submission comprised further analysis of certain clinical information that was previously provided to the FDA by the company. No additional data or studies have been requested.

16:28 EDT Metropolitan Commercial partners with Finzly for advanced payment processing - Metropolitan Commercial Bank announced a partnership with leading cloud-based payments platform, Finzly. By leveraging Finzly's modern payment hub, Metropolitan Commercial Bank aims to transform its payment processing operations on ACH, Fedwire, and FedNow. The Bank recognizes the importance of offering innovative and secure payment solutions to meet the changing needs of its customers. "We selected Finzly for its ability to cater not only to our business customers and consumers but also to foster robust partnerships within the payments industry," said Nick Rosenberg, EVP, Head of Global Payments Group, at Metropolitan Commercial Bank. "Through Finzly's advanced payment infrastructure, we now lead the way in delivering advanced payment experiences, positioning us at the forefront of financial innovation." In addition, the Bank plans to implement customized payment solutions that cater to the specific needs of its diverse business clients by integrating Finzly's innovative business banking platform.

16:25 EDT Cameco announces passing of board chair Ian Bruce - Cameco said it is mourning the accidental passing of its long-standing board member and board chair Ian Bruce on Sunday, October 15 at his cottage in Ontario. "We are heartbroken with this tragic loss of a dear friend and valued colleague. I have worked with Ian since he joined our board more than a decade ago. He was a dedicated husband and father who was very proud of his family. We extend our deepest condolences to Ian's wife Darlene, their family and their many friends and loved ones," said Tim Gitzel, president and CEO of Cameco. "Ian was also proud to be part of the Cameco family and his business acumen and leadership were invaluable to our board." Ian first joined Cameco's Board of Directors in 2012 and became board chair in May 2018, bringing over 30 years of experience in investment banking after serving as president and CEO of Peters & Co. Ltd. He also chaired the boards of MEG Energy Corporation and Qube Technologies Inc.

16:17 EDT American Equity reports Q3 total enterprise sales $2.2B - American Equity Investment Life Holding Company announced that its third-quarter 2023 sales totaled $2.2B, substantially all of which were in fixed index annuities. Third quarter 2023 sales were $2.2B, of which 99% were in fixed index annuities. Total enterprise FIA sales increased 18% compared to the second quarter of 2023 and 203% compared to the third quarter of 2022.

16:16 EDT Valmont to partner with FieldSync - Valmont(R) Industries "announced a strategic partnership with FieldSync, a pioneering provider of infrastructure data acquisition and analytics technology. This groundbreaking partnership represents a first of its kind, geared toward delivering innovative product solutions that drive digital transformation and provide customers with continued value. Aiming to better fuse climbing and drone inspection methods, the collection and delivery of inspection data, and recommendations for infrastructure management, the partnership between Valmont and FieldSync marks a significant milestone in the evolution of data acquisition and analytics in the telecommunications market. By combining Valmont's expertise as a global leader in creating vital infrastructure with FieldSync's cutting-edge technology solutions, the companies will jointly offer a comprehensive suite of advanced solutions to optimize the infrastructure lifecycle. Together, the two companies will be able to provide a total package, turnkey solution that includes structure purchase, initial and ongoing data collection, and recommendations for maintenance to extend service life."

16:12 EDT Terex CEO John Garrison, Jr. to retire, Simon Meester to succeed - Terex announced that John Garrison, Jr. is retiring as Chairman and CEO and a member of the Board of Directors, effective January 1, 2024. Garrison will be succeeded by Simon Meester, current President Terex Aerial Work Platforms, as the company's President and CEO. Meester will also join the company's Board. Garrison will work closely throughout the remainder of 2023 with Meester to ensure a seamless and orderly transition of responsibilities. Joshua Gross, current Genie Vice President of Global Strategy and Product Management, will be promoted to President Genie. Garrison will continue as a consultant for Terex after January 1, 2024 through June 30, 2024. David Sachs, currently lead independent director of the Terex Board will become Non-Executive Chairman of the Board effective January 1, 2024.

16:10 EDT Rhythm Pharma data show LT benefit of setmelanotide on hypothalamic obesity - Rhythm Pharmaceuticals announced several data presentations showing that setmelanotide therapy resulted in sustained and deepened weight loss in patients with severe obesity caused by rare MC4R pathway diseases during The Obesity Society's Annual Meeting at ObesityWeek..."We are excited to highlight the data showing meaningful, long-term benefits of setmelanotide in patients living with hyperphagia and severe obesity caused by rare MC4R pathway diseases at ObesityWeek," said David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm. "We believe the one-year BMI reduction of more than 25% in patients with hypothalamic obesity - where individuals trended towards normal body weight - is particularly encouraging as it shows continued improvement over our previously reported 16-week and six-month data. The hypothalamic obesity data affirm our confidence as we advance our pivotal, Phase 3 trial and work to bring setmelanotide to patients and families facing this challenging disease for which there are no approved, effective therapies."

16:08 EDT Viking Therapeutics announces results from Phase 1 clinical trial of VK2735 - Viking Therapeutics announced that new results from the company's Phase 1 single ascending dose, or SAD, and multiple ascending dose, or MAD, clinical trial of VK2735 were featured in an oral presentation at ObesityWeek 2023, the annual meeting of The Obesity Society. VK2735 is a novel dual agonist of the glucagon-like peptide 1, or GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP, receptors in development for the potential treatment of various metabolic disorders such as obesity. Highlights from the oral presentation include newly reported data demonstrating that 28 days of once-weekly treatment with VK2735 resulted in reductions in subjects' liver fat content and plasma lipid levels, both from baseline and as compared to placebo. Viking is currently conducting the Phase 2 VENTURE trial, a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and weight loss efficacy of VK2735, administered subcutaneously, once weekly, for 13 weeks. The VENTURE trial is evaluating the treatment in adults who are obese, or adults who are overweight with at least one weight-related co-morbid condition. The primary endpoint of the study is the percent change in body weight from baseline to Week 13, with secondary and exploratory endpoints evaluating a range of additional safety and efficacy measures.

16:07 EDT Y-mAbs Therapeutics announces FDA clearance of CD38-SADA IND application - Y-mAbs Therapeutics announced that the FDA has cleared the company's investigational new drug, or IND, application for CD38-SADA, the company's second program within its Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy Theranostic Platform. The Phase 1 trial is a first-in-human, dose-escalation, open-label, single-arm, multi-center trial investigating the safety and tolerability of the CD38-SADA: 177Lu-DOTA Drug Complex in patients with Relapsed or Refractory non-Hodgkin Lymphoma.

16:03 EDT BeiGene says Phase 3 RATIONALE 305 trial data show improved overall survival - BeiGene announced results from the final analysis of the Phase 3 RATIONALE 305 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) in the intent-to-treat (ITT) population as a first-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). No new safety signals were identified. Study results will be featured as a late-breaking oral presentation on October 21 at 5:25 p.m. CEST at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract #LBA80). "Gastric cancer is a devastating disease that affects millions of people worldwide. Unfortunately, patients with advanced or metastatic conditions have a poor prognosis and urgently need more treatment options in the first-line setting," said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. "These data show that tislelizumab plus chemotherapy resulted in significant overall survival improvement compared with chemotherapy alone in the intent-to-treat patient group. These results and positive findings build upon the data presented earlier this year in the high PD-L1 expression group and add to the growing body of evidence demonstrating the potential for tislelizumab to help patients with advanced gastric cancer or gastroesophageal junction cancer." In the final analysis of 997 intent-to-treat patients from the Phase 3 RATIONALE 305 trial, tislelizumab plus chemotherapy (oxaliplatin 130 mg/m2 IV Q3W (day 1) and oral capecitabine 1000 mg/m2 twice daily (days 1-14) Q3W (XELOX), or cisplatin 80 mg/m IV Q3W (day 1) and 5-fluorouracil 800 mg/m2/day IV (days 1-5) Q3W (FP)) showed a median OS of 15.0 months compared with an OS of 12.9 months for chemotherapy alone (HR: 0.80 [95% CI: 0.70, 0.92]; P = 0.0011) in first line advanced GC/GEJC.

16:02 EDT BeiGene says Phase 3 RATIONALE 315 trial met primary endpoints - BeiGene announced that the Phase 3 RATIONALE 315 study met its dual primary endpoints of major pathological response (MPR) by Blinded Independent Pathology Review (BIPR) and event-free survival (EFS) by Blinded Independent Central Review (BICR), demonstrating statistically significant and clinically meaningful improvements in patients with resectable Stage II or IIIA NSCLC treated with tislelizumab in combination with chemotherapy before surgery and as a single agent after surgery versus neoadjuvant chemotherapy plus placebo followed by placebo after surgery. The tislelizumab plus chemotherapy regimen also showed a statistically significant improvement in pathological complete response (pCR), the key secondary endpoint, after neoadjuvant therapy versus chemotherapy. The MPR and pCR data will be featured as a late-breaking mini oral presentation on October 23 at 2:55 p.m. CEST at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract #LBA58). In the study, 56.2% of NSCLC patients treated with tislelizumab in combination with chemotherapy before surgery achieved MPR, compared to 15.0% of patients treated with chemotherapy alone (difference: 41.1%; 95% CI: 33.2-49.1, pless than0.0001). MPR is defined as less than 10% residual viable tumor after neoadjuvant therapy. Additionally, 40.7% of patients on the tislelizumab-based regimen achieved pCR, defined as no viable residual tumor after neoadjuvant therapy, compared to 5.7% of patients treated with chemotherapy alone (difference: 35.0%; 95% CI: 27.9-42.1, pless than0.0001). Tislelizumab plus chemotherapy was generally well tolerated, with no new safety signals identified.

15:52 EDT Bristol Myers says Opdivo combination showed improvements in primary endpoints - Bristol Myers announced the first presentation of results from the Phase 3 CheckMate -901 trial, in which Opdivo in combination with cisplatin-based chemotherapy followed by Opdivo monotherapy demonstrated statistically significant and clinically meaningful improvements in the primary efficacy endpoints of overall survival, or OS, and progression-free survival, or PFS, as assessed by Blinded Independent Central Review, or BICR, compared to standard-of-care cisplatin-based chemotherapy as a first-line treatment for patients with unresectable or metastatic urothelial carcinoma who are cisplatin-eligible. With a median follow-up of approximately 33 months, treatment with Opdivo in combination with cisplatin-based chemotherapy reduced the risk of death by 22%, demonstrating a median OS of 21.7 months vs. 18.9 months with chemotherapy alone. At the 12- and 24-month landmark analyses, patients treated with upfront Opdivo plus chemotherapy experienced OS rates of 70.2% and 46.9%, respectively, compared to 62.7% and 40.7% with chemotherapy. In patients receiving the Opdivo-based combination, the risk of death or disease progression was reduced by 28%, with median PFS at 7.9 months compared to 7.6 months with chemotherapy. The landmark 12- and 24-month PFS rates were 34.2% and 23.5%, compared to 21.8% and 9.6% with chemotherapy. The combination of Opdivo with cisplatin-based chemotherapy had a tolerable safety profile consistent with the known safety profiles of the individual components of the regimen. No new safety concerns have been identified. Additionally, in exploratory analyses, Opdivo with cisplatin-based chemotherapy resulted in an approximately 15% higher objective response rate, or ORR, compared to chemotherapy alone and nearly doubled the number of patients who achieved a complete response. Opdivo in combination with cisplatin-based chemotherapy was associated with longer duration of response than chemotherapy, and median duration of complete response was nearly tripled.

15:08 EDT Founding Partners of Sculptor Capital sue over proposed merger with Rithm - The Founding Partners of Sculptor Capital Management (SCU), which include Daniel Och, Harold Kelly, Richard Lyon, James O'Connor and Zoltan Varga, announced that they filed a complaint against the company, its directors and Rithm Capital Corp (RITM) in the Delaware Court of Chancery. "The lawsuit seeks to stop the defendants from continuing to breach their fiduciary duties to the shareholders in connection with a proposed merger transaction between the company and Rithm," the group stated in a press release. The Founding Partners said: "The Special Committee's actions over the past several weeks remove any doubt that they favor only one result - the preservation of management's jobs and compensation, at the expense of shareholder value. Since the initial announcement of the Rithm transaction at $11.15 per share, the company's stock has been trading well above $12 per share, reflecting stockholders' expectations that the Special Committee would act to maximize value given the higher $13 per share offer from the Consortium. Despite these fundamental facts, the Special Committee has agreed to an amended deal with Rithm at only $12 per share. Worse yet, the Special Committee has imposed a series of extraordinary conditions designed to tilt the playing field against the Consortium or any other bidder and undermine stockholders' ability to vote down the Rithm deal. The Sculptor Board continues to prevent the Consortium from communicating directly with the public stockholders or the company's clients, and from negotiating with the Founders. In contrast, the Special Committee has readily waived Rithm's NDA to permit it to negotiate with the Founders and to purchase 6.5% of the vote from Delaware Life. Working together, the Special Committee and Rithm are pushing forward an inferior deal that protects Sculptor management at the expense of the public stockholders. In light of what we and others believe to be a flagrant breach of fiduciary duty, we have brought this action in an effort to force the company and its directors to maximize shareholder value."

14:45 EDT U.S. Bancorp up 10% after notice on Federal Reserve commitments - Shares of U.S. Bancorp are up $3.23, or 10%, to $35.85 in afternoon trading.

14:41 EDT Gyrodyne trading resumes

14:12 EDT Southwestern Energy up 7% after Reuters says Chesapeake interested in tie-up

13:18 EDT AutoNation withdraws from Pendragon process - AutoNation (AN) confirmed that it will not be making a formal offer for Pendragon PLC (PDGNF). On September 26, AutoNation confirmed that it had submitted a preliminary, non-binding proposal to acquire the entire issued and to be issued share capital of Pendragon PLC. After further considering the opportunity, AutoNation today confirmed, as required by Rule 2.8 of the U.K. City Code on Takeovers and Mergers, that it does not intend to make an offer for Pendragon. Mike Manley, AutoNation's CEO, stated, "These assets presented AutoNation with a potential opportunity to expand into a new market. However, after further considering the opportunity, we decided not to make a formal offer. AutoNation will continue to leverage M&A, which may include opportunities within and outside the U.S., to expand our business portfolio in a meaningful and synergistic way, and to create value for our shareholders."

13:05 EDT Stellantis announces cancellation of CES 2024 plans - Stellantis stated: "As the costs of the ongoing UAW strikes against Stellantis continue to mount, the company has decided to cancel its planned display and presentations at CES 2024, the world's largest technology show, scheduled for January 2024 in Las Vegas, Nevada. Being second to none in value creation for all stakeholders - customers, employees and investors - is a key component of the Stellantis Dare Forward 2030 strategic plan. In light of the current status of negotiations in the United States, preserving business fundamentals and therefore protecting the future of the company is a top priority of Stellantis leadership."

12:22 EDT LL Flooring falls 1% to $3.56 after cautious Bleecker Street report

12:08 EDT Wyndham Hotels & Resorts trading resumes

12:00 EDT VMware falls -6.3% - VMware is down -6.3%, or -$11.23 to $167.65.

12:00 EDT Enerpac Tool rises 11.1% - Enerpac Tool is up 11.1%, or $2.90 to $28.89.

12:00 EDT a.k.a. Brands rises 14.3% - a.k.a. Brands is up 14.3%, or $1.00 to $7.98.

11:48 EDT Nvidia, chip peers slide after U.S. strengthens restrictions on advanced semis - Shares of Nvidia (NVDA) and several other semiconductor makers are sliding after the U.S. Department of Commerce's Bureau of Industry and Security, or BIS, released a package of rules designed to update export controls on advanced computing semiconductors and semiconductor manufacturing equipment, as well as items that support supercomputing applications and end-uses, to arms embargoed countries, including the PRC, and to place additional related entities in the PRC on the Entity List. "Today's rules reinforce the October 7, 2022, controls to restrict the PRC's ability to both purchase and manufacture certain high-end chips critical for military advantage. These updates are necessary to maintain the effectiveness of these controls, close loopholes, and ensure they remain durable," the BIS stated. "Today's updated rules will increase effectiveness of our controls and further shut off pathways to evade our restrictions. These controls maintain our clear focus on military applications and confront the threats to our national security posed by the PRC Government's military-civil fusion strategy. As we implement these restrictions, we will keep working to protect our national security by restricting access to critical technologies, vigilantly enforcing our rules, while minimizing any unintended impact on trade flows," added Secretary of Commerce Gina Raimondo. Other publicly traded companies in the chip making and equipment space include AMD (AMD), Intel (INTC), Marvell (MRVL), Microchip (MCHP), Micron (MU), Qualcomm (QCOM), Texas Instruments (TXN), ASML (ASML), Applied Materials (AMAT), Lam Research (LRCX) and KLA Corp. (KLAC). Reference Link

11:13 EDT Rite Aid announces court approval of 'First Day' motions - Rite Aid (RADCQ) announced that it has received approvals from the U.S. Bankruptcy Court for the District of New Jersey for its "First Day" motions related to the company's voluntary Chapter 11 petitions filed on October 15. The Court granted interim approval to access up to $3.45B in debtor-in-possession financing from certain of its lenders. This financing is expected to provide sufficient liquidity to support the company throughout this process. Among other things, the Court has authorized the company to continue to pay associate wages, salaries and benefits without interruption, pay vendors and suppliers in full for goods and services provided on or after the filing date of October 15 and otherwise continue to deliver leading healthcare products and services across its retail and online platforms. "As previously announced, Rite Aid reached an agreement in principle with certain of its senior secured noteholders on the terms of a financial restructuring plan that will allow the company to accelerate its ongoing business transformation. Implementing the contemplated restructuring plan will significantly reduce the company's debt, increase its financial flexibility and enable it to execute on key initiatives. Additionally, as previously announced, Rite Aid has also entered into an agreement with MedImpact Healthcare Systems, an independent pharmacy benefit solutions company, pursuant to which MedImpact will acquire Rite Aids' Elixir Solutions business. Under the terms of the agreement, MedImpact will serve as the "stalking horse bidder" in a court-supervised sale process under section 363 of the U.S. Bankruptcy Code. Accordingly, the proposed transaction is subject to higher and better offers, court approval and other customary conditions. Elixir Solutions is operating normally and continuing to serve clients, plan sponsors, members and customers as usual. Elixir Insurance is not included in Rite Aid's Chapter 11 process or the proposed transaction with MedImpact, and it is continuing to operate and serve members as usual," the company stated.

11:09 EDT Cadence Design joins Arm Total Design - Cadence Design Systems (CDNS) announced it has joined Arm (ARM) Total Design, aimed at "supporting and accelerating the development of highly differentiated custom SoCs based on Arm Neoverse Compute Subsystems." Cadence said: "As part of this collaboration, Arm and Cadence customers can accelerate their SoC design process through access to Cadence's full-flow system-level design verification and implementation solutions. Neoverse CSS delivers world-class performance for the latest Arm CPUs and system IP on leading-edge technology. Cadence joining Arm Total Design will help mutual customers create differentiated products on a verified, customizable subsystem while reducing development costs, minimizing risk, and shortening the time-to-market for designs."

11:07 EDT Synopsys announces expanded collaboration with Arm - Synopsys (SNPS) announced it has expanded its collaboration with Arm (ARM) to provide optimized IP and EDA solutions for the newest Arm technology, including the Arm Neoverse V2 platform and Arm Neoverse Compute Subsystem. "Synopsys has joined Arm Total Design where Synopsys will leverage their deep design expertise, the Synopsys.ai full-stack AI-driven EDA suite, and Synopsys Interface, Security, and Silicon Lifecycle Management IP to help mutual customers speed development of their Arm-based CSS solutions. The expanded partnership builds on three decades of collaboration to enable mutual customers to quickly develop specialized silicon at lower cost, with less risk and faster time to market," the company announced.

10:54 EDT Engaged Capital sees potential to triple VF Corp. share price in under 3 years - Engaged Capital, which identifies itself as an investment firm specializing in enhancing the value of small and mid-cap North American companies and "a top shareholder" of V.F. Corporation, the owner of The North Face and Vans brands, issued a presentation highlighting what it calls "the actionable and significant opportunities for long-term value creation" at the company. Engaged outlines actions it sees having the "potential to triple VF Corp.'s share price in less than three years" and expresses a desire to "work with company leadership" to refresh the board and "drive sustained value." The firm shared a presentation delivered at the 13D Monitor Active-Passive Investor Summit related to its V.F. Corporation plan. Reference Link

10:37 EDT Wyndham Hotels & Resorts trading halted, news pending

10:11 EDT Puyi subsidiary announces strategic cooperation agreement with Ping An Bank - Puyi Fund, a subsidiary of Puyi Inc., and Ping An Bank Co., recently announced that they have formally entered into a strategic cooperation. "Under the strategic cooperation framework, Ping An Bank and PUYI Fund will establish a long-term cooperative relationship. In order to safeguard the common interests and promote the common development of both parties, they will actively commit themselves to constructive business co-operation in the field of finance, give full play to their respective industrial strengths, integrate the resources of both parties, pool their synergies, realize bi-directional empowerment, and work hand in hand to push forward the high-quality synergistic development. According to the strategic cooperation agreement, both parties will engage in business collaboration while adhering to the respective business regulations. The collaboration encompasses various financial services such as wealth management, account system services, fund investment and research services, personal pension investment accounts, personal finance planning and bank financing services. Furthermore, both parties will foster profound cooperation and innovation in customer management, product management, channel management and data management in order to deliver cutting-edge financial products and services," Puyi stated in a press release.

10:05 EDT CAE launches Master Technician Program for business aircraft maintenance - CAE announced at the NBAA Business Aviation Conference and Exhibition the launch of its Master Technician Program for organizations and individuals who seek to attain the highest standards of technical excellence and professionalism in business aircraft maintenance. The new program builds on CAE's previous Master Technician program by offering technicians the flexibility to enhance their skills and competencies along two distinct tracks: Specialist and People Leader. The new Master Technician Program addresses the need for independent certification of technical and leadership skills as the industry faces unprecedented demand for aircraft maintenance technicians. CAE's 2023 Aviation Talent Forecast predicts a need for 402,000 new maintenance technicians industrywide over the next 10 years - 74,000 in business aviation.

10:02 EDT Walmart opens fulfillment center near Dallas - Walmart associates were joined by local elected officials and community members to celebrate the grand opening of a new 1.5 million square-foot fulfillment center 15 miles south of Dallas, located at 2500 Belt Line Road in Lancaster. This next generation facility will enable the retailer to fulfill more orders, more quickly. The Lancaster fulfillment center is the third of four next generation facilities announced last year. A fifth facility was recently announced that will open in 2026. These next generation facilities bring the powerful combination of people, technology and machine learning together to achieve faster shipping and delivery, while increasing Walmart.com order fulfillment capacity. The Lancaster fulfillment center will be home to more than 1,000 Walmart associates. The retailer is currently hiring for a variety of positions, including tech-focused jobs. Each job brings with it a pathway for opportunity at Walmart.

10:00 EDT VeriSign Inc falls -7.4% - VeriSign Inc is down -7.4%, or -$3.05 to $38.22.

10:00 EDT VMware falls -7.9% - VMware is down -7.9%, or -$14.16 to $164.72.

10:00 EDT VF Corp. rises 8.8% - VF Corp. is up 8.8%, or $1.42 to $17.61.

09:59 EDT Goldman Sachs: Impact of tightening to be more evident in 2-4 quarters

09:50 EDT Tempest Therpeutics trading resumes

09:47 EDT VeriSign Inc falls -6.1% - VeriSign Inc is down -6.1%, or -$2.53 to $38.74.

09:47 EDT VMware falls -10.9% - VMware is down -10.9%, or -$19.41 to $159.47.

09:47 EDT Direxion Daily Semiconductor Bear 3X Shares rises 6.9% - Direxion Daily Semiconductor Bear 3X Shares is up 6.9%, or 72c to $11.20.

09:45 EDT Goldman got $15B of capital call facilities from Signature, says CFO Coleman

09:43 EDT VF Corp. jumps 8% to $17.57 after WSJ report of activist stake

09:40 EDT Johnson & Johnson says 'confident' in product pipeline for 2024/2025 - Says "very pleased" with performance of MedTech business. Expects to file for regulatory approval for lung cancer therapy in 2025. Says immunology portfolio remains "key driver of growth."

09:39 EDT Goldman CEO: Proposed capital rules would negatively impact competitive standing - If proposed capital rules are implemented, more activity will move to shadow banks, says CEO David Solomon.

09:36 EDT Goldman Sachs CEO: U.S. economy more resilient than expected

09:31 EDT AirSculpt Technologies partners with singer Joey Fatone - AirSculpt is partnering with singer, dancer, actor, and TV personality Joey Fatone to share his AirSculpt experience. Over the coming weeks, follow along at @airsculpt and Joey's Instagram @realjoeyfatone to see his experience and final results that were achieved with AirSculpt.

09:29 EDT Veritiv stockholders approve acquisition by Clayton, Dubilier & Rice - Veritiv stockholders voted in favor of all proposals, including a proposal to approve the company's pending acquisition by an affiliate of Clayton, Dubilier & Rice. Closing of the transaction is subject to customary closing conditions including the receipt of required regulatory approval and is expected to take place in Q4.

09:26 EDT Cardio Diagnostics Aimil team on detection and management of CHD in India - Cardio Diagnostics Holdings announced a significant move to transform global cardiovascular health, by entering into a Supply and Distribution Agreement with one of India's premier organizations, Aimil. Aimil, a company involved in the instrumentation industry in India since 1932 with 14 sales and services offices across India, is a leader in introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India. ...This strategic venture between Cardio Diagnostics and Aimil seeks to address the growing prevalence of heart disease in India through the introduction of Cardio Diagnostics' clinical test, Precision CHD, for the detection and personalized management of coronary heart disease or CHD.

09:20 EDT Mondee expands share repurchase program to up to $40M - Mondee announced the increase of its existing Preferred Equity Financing by up to $15M. Consequently, the Company's Board of Directors has authorized a $10 million expansion of the Company's on-going share repurchase program, bringing the total size of the common stock repurchase program authorized by the Board of Directors to up to $40M. All other terms of the repurchase program remain unchanged. The Company has completed an amendment to its existing Preferred Equity Financing including issuing additional preferred shares for an amount of up to $15 million, $10 million of which has already been funded. The Preferred Equity continues to accumulate preferred dividend with no requirement on the part of the Company to make any cash payments pursuant to the instrument unless the investors exercise its put option in 2026. Mondee's Chairman, CEO and Founder, Prasad Gundumogula, commented, "We are excited to further strengthen our balance sheet with additional liquidity and increase our share repurchase program, signaling our strong financial position and continued confidence in our business strategy. This expansion reflects our commitment to creating value for our shareholders while maintaining financial flexibility." As of now, the Company has repurchased less than $5 million of common stock originally authorized for repurchase under the program.

09:17 EDT Senmiao Technology signs agreement with Xingyuan for auto supply chain financing - Senmiao Technology's operating subsidiary Hunan Xixingtianxia Technology has signed a strategic cooperation agreement with Sichuan Xingyuan Ronghe New Energy. Xingyuan provides automobile supply chain financing to major online ride-hailing platforms in China and invests, builds and operates new energy battery swap stations. With more than 10,000 new energy vehicles in operation for online ride-hailing services in 12 cities in China, including Hangzhou, Shenzhen and Guangzhou, Xingyuan operates the fifth-largest number of owned NEVs for online ride-hailing enterprises nationwide. Xingyuan will provide comprehensive financing solutions for Senmiao and its channel and merchandise partners. Senmiao will introduce Xingyuan to its online ride-hailing services partners. In addition, Xingyuan will provide Senmiao with resources such as discounted NEV purchasing channels and new energy battery swapping vehicle operations.

09:14 EDT Johnson & Johnson says continues to pursue four-pronged talc litigation strategy - Expects to continue to "vigorously defend" against talc claims.

09:12 EDT Hanryu Holdings partners with Asia Model Festival for engagement events - Hanryu announced that the main event of Asia Model Festival, with their participation as the main sponsor, is scheduled to take place from late October through November 2023 that will grow brand reach and recognition of FANTOO, as well as expand user base to Fandom of Asia Model. The promotional events that Hanryu is supporting with Asia Model Festival include: Model Camp; Asia Open Collection; FACE of ASIA; Asia Model Awards. Kang Chang Hyuk, the CEO of Hanryu Holdings, stated, 'Building on our strong relationship with the Asia Model Festival, Hanryu is a major sponsor of the event, and believes it is a great opportunity for Asian cultures to come together to celebrate their backgrounds, including k-culture. The festival has already brought meaningful activities at FANTOO by the power of Fandom of Asia Model, and provides an opportunity for the FANTOO brand to be front and center on a global stage and allows consumers to better get to know our leadership position in k-culture. We are delighted to be a part of this event and look forward to seeing the FANTOO brand and Fandom of Asia Model widely featured'.

09:12 EDT Momentus signs contract with SatRev for 2024 orbital delivery, no terms - Momentus has signed a contract with SatRev for transportation and orbital delivery services in 2024. SatRev is a Polish company established in 2016 that specializes in building small, lightweight nanosatellites. The company has contracted to fly its SOWA-1 payload with Momentus in the first quarter of next year. "Earth observation data informs and empowers, and SatRev is making great strides in that part of the industry," said Momentus Chief Commercial Officer Chris Kinman. "Momentus' transportation services are efficient and economical, and we're always glad to help our customers find the best path to their orbital destination." In addition to rideshare missions, Momentus offers Delta-V delivery for missions requiring precise custom orbits. The Company also provides hosted payload services and its M-1000 satellite bus for customized and dedicated missions.

09:10 EDT Mattel announces collaboration with Paramount on new toy line - Mattel (MAT) announced the collaboration between its brand, Masters of the Universe and the iconic franchise, Paramount's (PARA) Teenage Mutant Ninja Turtles, to unveil The Masters of the Universe Origins Turtles of Grayskull toy line. Combining the power of Eternia with the sewer-dwelling heroes of New York, The Masters of the Universe Origins Turtles of Grayskull toy line represents an overlap of two worlds to celebrate the 40th anniversary of Teenage Mutant Ninja Turtles in 2024.

09:10 EDT Coveo Solutions announces 15 enhancements to Coveo Platform - Coveo announced more than 15 new enhancements to the Coveo platform. These innovative enhancements strengthen the Coveo composable AI Search and Generative experience platform to improve digital experiences across commerce, service, website and workplace to deliver superior business outcomes for enterprises.

09:09 EDT Broadcom announces availability of Qumran3D - Broadcom announced the immediate availability of Qumran3D, the next generation of the StrataDNX family of single chip routers. A leading-edge single chip, Qumran3D offers 25.6 Terabits per second of routing in a fixed form factor, with Ethernet port rates from 100 Gb/s to 800 Gb/s. A routing solution based on a single Qumran3D will save up to 66% more energy and up to 80% more rack space compared to previous generations. "Qumran3D will accelerate the transition to merchant silicon routers," said Ram Velaga, senior vice president and general manager, Core Switching Group, Broadcom. "With its unique combination of unyielding performance, power efficiency and security, Qumran3D is the ideal solution for the next generation of fixed, standalone routers. It will revolutionize the way that operators build and manage their networks."

09:07 EDT CareCloud announces major credentialing partnership with large U.S. corporation - CareCloud announced a major credentialing partnership with a large, publicly-traded U.S. corporation that stands as a frontrunner in the healthcare technology sector. CareCloud initiated its partnership with the Company in late 2022 when the Company engaged in a substantial multi-million dollar agreement to leverage CareCloud Force, a workforce extension solution designed to bolster healthcare capabilities. As part of this evolving collaboration, CareCloud will now extend its credentialing services to the Company, thereby expanding the reach of CareCloud's credentialing services to a vast customer base encompassing tens of thousands within the Company's network. Karl Johnson, president of CareCloud Force, stated, "The Company, specializing in revenue cycle management services, found itself struggling with the challenge of client credentialing. CareCloud's comprehensive credentialing can help tie things together for this Company, streamlining the process, reducing errors, and ensuring timely enrollment.

09:05 EDT Rail Vision receives $500,000 order from leading LATAM mining company - Rail Vision received a $500,000 purchase order for a single MainLine system and related services from a leading Latin American, LATAM, mining company. This MainLine system is expected to be delivered to the new customer during the fourth quarter of 2023. "We have now expanded our global footprint into the massive LATAM market with this purchase order from a leading multinational mining company," said Shahar Hania, CEO of Rail Vision. "This is the second major mining company to use Rail Vision's innovative AI-enabled obstacle detection solutions, strengthening our foothold in an attractive market segment. We are confident that our MainLine system will bring significant value to this customer by enhancing their safety and operational efficiency."

09:04 EDT Syra Health awarded two-year contract extension with Indiana Outcomes Workgroup - Syra Health announced a two-year contract extension, worth up to $636K, with the Indiana Division of Mental Health and Addiction and Family and Social Services Administration - FSSA - to chair and manage the State of Indiana's Epidemiological Outcomes Workgroup, or SEOW. Through the contract extension, Syra Health will continue to collect and analyze substance use and misuse data throughout Indiana. Syra Health then develops data-driven reports and recommendations to inform and improve Indiana's long-term substance misuse prevention policy.

09:03 EDT Sun Country Airlines to expand international service to two Canadian cities - Sun Country Airlines will launch new nonstop service to YUL Montreal-Trudeau International Airport and Toronto Pearson International Airport in June of 2024. Sun Country has also extended its schedule for customers to book travel through Sept. 10, 2024. In addition to Montreal and Toronto, the schedule extension includes eight new domestic, seasonal nonstop routes from Minneapolis-St. Paul International Airport to: Albuquerque International Sunport, New Mexico; Billings Logan International Airport, Montana; Boise Airport, Idaho; Dulles International Airport, Virginia/Washington, D.C.; Gerald R. Ford International Airport, Grand Rapids, Michigan; Missoula Montana Airport, Montana; Oakland International Airport, California;Syracuse Hancock International Airport, New York. Service to the new destinations will generally be twice weekly with service to Dulles four times a week. With these new destinations, Sun Country will offer nonstop service from MSP to 98 distinct markets in 2024.

09:02 EDT Lucid Group reports vehicle production of 1,550 in Q3 - Lucid Group reported production and delivery totals for Q3. Lucid produced 1,550 vehicles during Q3, plus over 700 additional vehicles in transit to Saudi Arabia for final assembly. The company delivered 1,457 vehicles during the same period.

08:59 EDT Johnson & Johnson says continues to make progress on new product launches - Says continues to invest in R&D at "competitive levels." Says well positioned to grow business and innovate across healthcare. Says Kenvue separation accomplished within target date and budget. Says IRA drug price settings are damaging to innovation. Expects to exit certain product lines in orthopedics over next few years. Says capital allocation priorities "remain unchanged." Says "positive momentum" heading into 2024. Comments taken from Q3 earnings conference call.

08:59 EDT OSI Systems receives $24M in orders from U.S. government customer - OSI Systems announced that its Security division has received orders valued at approximately $24M in aggregate from a U.S. government customer. As part of these awards, Rapiscan will provide our latest cargo and vehicle inspection systems, including installation, training, and support. Additionally, the Company will provide ongoing maintenance service and support on our existing non-intrusive inspection solutions in the field.

08:58 EDT Bank of America sees Q4 NII roughly $14.4B

08:51 EDT Mawson Infrastructure reports 89 self-mined bitcoin in September - Rahul Mewawalla, CEO and President, commented, "We are pleased that the total number of Bitcoin self-mined in Q3 grew significantly by approximately 35% sequentially to 246 BTC, up from 182 BTC last quarter. The ongoing successful implementation of our new operating excellence model combined with our overall business and technology optimization efforts have enhanced our operating metrics and continues to uplift our self-mining business performance. Moreover, Mawson's self-mining business expanded in September increasing by 7% M/M growing to approximately 16,730 miners online and hashing, and the number of self-mined Bitcoin in September also increased month-on-month to 89 BTC."

08:46 EDT AIM ImmunoTech engages Azenova for Ampligen pipeline programs - AIM ImmunoTech entered into an agreement with Azenova to support efforts to partner AIM's pipeline programs with a particular focus on the company's lead asset, Ampligen, for the treatment of various malignant solid tumors. Azenova has been engaged to assist AIM with its BD efforts with the goal of entering into a partnership, out-license or other transaction whereby a biopharmaceutical company takes on the further development and commercialization of Ampligen with the goal of maximizing value to AIM. This process may not result in any transaction and the company does not intend to disclose additional details unless and until it has entered into a definitive agreement.

08:45 EDT HCA Healthcare and Grail team on multi-cancer early detection screening - HCA Healthcare Sarah Cannon Cancer Institute, part of HCA Healthcare, and GRAIL , a healthcare company with a mission of detecting cancer early when it can be cured announced a strategic collaboration to advance comprehensive cancer care through early detection. Starting today, GRAIL's Galleri multi-cancer early detection MCED test will be available to patients who meet screening criteria at select HCA Healthcare physician practices..."HCA Healthcare and Sarah Cannon are aligned with GRAIL's mission to improve the detection of cancer at earlier stages, when the chances of successful treatment are higher," said Jeffrey Venstrom, MD, chief medical officer at GRAIL. "In addition to HCA Healthcare offering the Galleri test, the use of Sarah Cannon Cancer Institute's nurse navigation program to support both patients and healthcare providers around MCED screening is the first of its kind. This program will provide critical insights about cancer detection and appropriate diagnostic follow-up."

08:44 EDT Upexi's Tytan Tiles launches Frozen product on Amazon - Upexi announced the Company's children's toy brand, Tytan Tiles, has launched its first licensed product under the agreement previously announced with The Walt Disney Company. The Disney Frozen Castle has been launched exclusively on Amazon.

08:42 EDT BofA managing expenses without large-scale layoffs, says CEO

08:42 EDT Foremost Lithium finalizes acquisition of Little Granite Gold/Silver Mine - Foremost Lithium Resource & Technology announced that it has made the third and final cash payment in the amount of $25,000USD to acquire a 100% interest in and to the Little Granite Gold/Silver Mine claims within the Winston Group of Properties as previously announced on December 14, 2022. Under the amended terms of this acquisition, Foremost successfully negotiated a reduction in the final cash payment required to exercise its option to acquire the Property from $380,000USD to $75,000USD which had been satisfied through the issuance a non-interest-bearing promissory note to the arm's length Property Vendor. The Note was due and payable by October 15, 2023 and, following the amendments, the Company has now acquired the Property for aggregate consideration of $186,000USD versus aggregate consideration of $434,000USD under the original terms of the acquisition.

08:40 EDT NeuroSense provides Q3 update - NeuroSense provided an update from its CEO, Alon Ben-Noon, on the company's clinical and operational developments during and immediately following Q3. The company's amyotrophic lateral sclerosis - ALS - Phase 2b PARADIGM trial of PrimeC is expected to report clinical topline results in Q4, and a Phase 2 Alzheimer's disease study is expected to enroll the first patient in the next several weeks. PrimeC was shown to significantly increase survival rate of induced motor neurons in an in vitro study utilizing induced pluripotent stem cells - iPSCs - generated from people living with ALS. In another independent study, PrimeC performed among the best in improving motor neuron survival when compared to several other ALS drugs in development and two ALS FDA approved drugs. NueroSense received Small and Medium-Sized Enterprise status from the EMA & opened office in Germany. SME status offers regulatory guidance and engagement in dialogue with EMA. The company is fully funded into Q2 2024 beyond clinical Phase 2b ALS results expected Q4 2023.

08:40 EDT Bank of America: Headcount down 7,000 FTEs from peak in January

08:39 EDT ABVC BioPharma announces update for ADHD Phase IIb study - ABVC BioPharma announced an update on the Company's eight-week long ADHD Phase IIb clinical study taking place at the University of California San Francisco, UCSF, Medical Center and five Taiwanese medical centers. Sixty-nine subjects enrolled in the study, 50 completed the study, and 11 are currently undergoing treatment. The study entitled "A Phase IIb Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients with Adult Attention-Deficit/Hyperactivity Disorder" is a randomized, double-blind, placebo-controlled study involving a total of approximately 100 patients in the United States and Taiwan. The Phase IIb clinical study continues the Phase IIa clinical study of ABV-1505. "We received a favorable response from the subjects participating in our ADHD Phase IIb study at all of our sites," said ABVC BioPharma Chief Executive Officer Uttam Patil, Ph. D. "To reach an interim analysis, the study requires 69 patients' data. Our clinical trials continue to demonstrate that medicine derived from plants can have significant therapeutic benefits, often with few - if any - side effects. We expect to report similar results in our interim analysis report."

08:37 EDT DarioHealth's Dario shows reduction of diabetes patient hospital readmissions - DarioHealth (DRIO) announced new research presented by Sanofi (SNY) at the Academy of Managed Care Pharmacy's 2023 annual conference Nexus ("AMCP-Nexus"), demonstrating a 36% reduction in 30-day hospital readmissions for Dario users compared to non-users living with type 2 diabetes. The research examined real-world claims data to determine whether users engaged with Dario's solution demonstrated less costly utilization of hospital-related utilization and found clinically meaningful impacts: 36% reduction in 30-day hospital readmission rate; and 1.6 fewer days in the hospital. The research is part of an ongoing study initiative conducted jointly by Dario and Sanofi U.S., and complements previously published studies presented at ISPOR demonstrating Dario's ability to reduce all-cause healthcare utilization by 9% and inpatient hospitalizations by 23%. Two additional analyses presented at AMCP Nexus by Sanofi U.S. examined clinical improvements in the same exact and propensity-score matched populations of Dario users and non-Dario users living with Type 2 diabetes.

08:36 EDT AAR Corp. has signed a multi-year contract extension with MTU Maintenance - AAR has signed a multi-year contract extension with MTU Maintenance, the global market leader in customized solutions for aero engines, to supply parts for Pratt & Whitney PW2000 engines. This fourth extension marks the continuation of an AAR-MTU contract that originally began in 2009. Under the agreement, AAR supplies used serviceable material for the PW2000 engine program at MTU's facility in Hannover, Germany. This partnership significantly streamlines logistical processes and creates cost efficiencies for MTU Maintenance's customers. "AAR is thrilled to continue supporting valued customer MTU on the PW2000 engines," said Christine Bognar, AAR's PW2000 Product Director. "The AAR-MTU relationship is a successful partnership providing mutual benefit, and we look forward to collaborating on the next chapter."

08:35 EDT Bank of America sees customer spending slowing down, says CEO Moynihan - Comments taken from Q3 earnings conference call.

08:35 EDT Luna Innovations names George Gomez-Quintero as CFO - Luna Innovations announced that George Gomez-Quintero is joining the company as Chief Financial Officer CFO today. Mr. Gomez-Quintero will succeed current CFO Gene Nestro, who has agreed to assist the company through mid-2024 to ensure a smooth transition. Mr. Gomez-Quintero will lead Luna's Finance organization and represent Luna in communications with investors, lenders and rating agencies. As a member of the company's executive team, he will report to President and CEO Scott A. Graeff. Prior to Intelsat, Gomez-Quintero was the Chief Operating Officer at JSI, a leader in broadband solutions and consulting. He previously held senior financial roles at XFL, Time Warner Cable and Cleartel Communications. He holds an M.B.A. from Cornell University and a B.B.A., Finance, from Iona College.

08:34 EDT Arteris IP enters partnership with Fraunhofer IESE - Arteris and Fraunhofer IESE announced they have partnered to enable interoperability between Arteris' FlexNoC and Ncore network-on-chip, NoC, development environment and Fraunhofer IESE's DRAM subsystem design space exploration framework. The interoperability will improve performance, reduce cost and accelerate the schedule of advanced DRAM-centric NoC development for mutual customers.

08:32 EDT Imax and GSC expand partnership with six Imax locations in Malaysia - Imax and Golden Screen Cinemas, or GSC, announced an expansion of their partnership with an agreement for six Imax with Laser systems in Malaysia. The agreement will see five new locations, including one in the heart of Kuala Lumpur and one upgrade to the Southkey Megamall, Johor Bahru. Under the new agreement, Imax has now completed deals in 2023 for 13 new and upgraded systems across Malaysia - more than any international market worldwide. This deal will bring the total number of Imax locations with GSC to nine, all of which will now feature Imax with Laser systems by 2027.

08:32 EDT ZimVie launches Azure Multi-Platform Product Solutions - ZimVie announced the recent launch of Azure Multi-Platform Product Solutions, a comprehensive selection of restorative components to effectively cater to the dental laboratory market. These new offerings are currently available in the United States and select markets in Europe, with future geographic expansion planned. This first launch in the Azure Multi-Platform Product Solutions category consists of 13 dental laboratory-focused prosthetic and restorative solutions designed to integrate into digital workflows. Dental laboratories now have the flexibility to select the right solution for every case, all without sacrificing the quality customers expect, the profitability laboratories demand, and the customer support they deserve. This broadens ZimVie's presence in patient-specific restorative dentistry, creating a holistic product portfolio that meets dental laboratories' needs, as a one-stop shop, for nearly everything related to tooth replacement.

08:24 EDT Digital Ally appoints Daughtery to board of directors - Digital Ally (DGLY) announced that the Board of Directors of the Company appointed D. Duke Daughtery as a member of the Board, effective immediately, to hold office until the next meeting of shareholders of the Company at which directors are being elected or as set forth in the Company's bylaws. Daughtery will immediately serve on the Board, with the intention to move to Kustom Entertainment's Board of Directors upon the completion of the recently announced transaction with Clover Leaf Capital Corp. (CLOE) .

08:22 EDT Thermo Fisher to acquire Olink for $26.00 per share in cash, sees accretion - Thermo Fisher (TMO) and Olink (OLK) announced that their respective boards of directors have approved Thermo Fisher's proposal to acquire Olink for $26.00 per common share in cash, representing $26.00 per American Depositary Share, or ADS, in cash. This represents a premium of approximately 74% to the closing price of Olink's American Depositary Shares that trade on Nasdaq on October 16, the last trading day prior to the announcement of the transaction. Thermo Fisher will commence a tender offer to acquire all of the outstanding Olink common shares and all of the American Depositary Shares. The transaction values Olink at approximately $3.1B which includes net cash of approximately $143M. Headquartered in Sweden, Olink has operations in the Americas, Europe and Asia Pacific. The transaction, which is expected to be completed by mid-2024, is subject to customary closing conditions, including receipt of applicable regulatory approvals, and completion of the tender offer. As part of the transaction, Summa Equity AB, Olink's largest shareholder and additional Olink shareholders and management, in aggregate holding more than 63% of Olink's common shares, have entered into support agreements agreeing to tender into the tender offer. Thermo Fisher expects to fund the acquisition using cash on hand and debt financing. Upon completion, Olink will become part of Thermo Fisher's Life Sciences Solutions segment. Olink is on track to deliver over $200M of revenue in 2024 and, as part of Thermo Fisher, is expected to grow mid-teens organically. In the first full year of ownership, the transaction is expected to be dilutive to adjusted EPS by 17c. Excluding financing costs and non-cash deal related equity compensation costs, the transaction is expected to be accretive by 10c in that period. Thermo Fisher expects to realize approximately $125M of adjusted operating income1 from revenue and cost synergies by year five following close. The expected strong long-term business growth and synergy realization profile make the financial returns on the transaction very compelling.

08:21 EDT Moolec Science announces $30M capital raise - Moolec Science entered into agreements to issue a convertible note due 2026 to Grupo Insud in a principal amount of approximately $21 million with a strike price of $6.00 per share. The Insud Convertible Note will be issued against a cash payment of $10 million and in-kind contributions to be made by Insud to Moolec. In-kind contributions include credits to access Insud's state-of-the-art industrial capabilities, operational services, and the incorporation of Joint Venture participation, started with Moolec in 2021. At maturity, Moolec will hold the option to deliver ordinary shares, cash, or a combination of cash and ordinary shares.

08:20 EDT Bausch Health announces results from analysis of adjudicated claims data - Bausch Health Companies announced findings from a retrospective database analysis of adjudicated claims data that examined the impact of access barriers for commercially-insured adults prescribed Xifaxan for reduction in risk of overt hepatic encephalopathy recurrence in adults. Results suggest potentially critical treatment gaps due to access barriers, which may result in increased rates of OHE-related hospitalizations. Findings from the analysis, "Assessment of Access Barriers to Rifaximin Among Patients with Overt Hepatic Encephalopathy Using Adjudicated Claims Data," were presented today at the AMCP Nexus 2023 meeting. Treatment gaps were assessed across a 12-month period that began at the first observed attempt to access rifaximin, which is defined as a paid, reversed or rejected prescription claim. Across the study period, patients had 8.8 average attempts to access rifaximin with an average 6.4 claims paid, 1.5 rejected and 0.9 reversed Nearly all patients experienced a treatment gap of at least one day, with an average of 2.9 gaps per patient leading to a total duration of 157.4 days without exposure to rifaximin. Treatment-initiated delays in receiving rifaximin were experienced by 34.8% of patients with more than three-quarters of initiation delays experienced due to rejected claims with the most common rejection reported as Prior Authorization Required. Following initial paid claim, active treatment gaps were experienced by nearly three-quarters of patients with an average gap duration of 22.9 days. The retrospective database analysis used the IQVIA PharMetrics Plus database linked with Longitudinal Access and Adjudicated Data and identified 1,711 commercially insured adults with OHE who had at least one paid rifaximin prescription fill and 12-month continuous eligibility.

08:18 EDT NextCure announces presentation of preclinical data on NC605 - NextCure announced the presentation of new preclinical data demonstrating that treatment with NC605, a novel anti-Siglec-15 antibody, reduced bone loss and enhanced bone quality in mice with osteogenesis imperfecta, OI, at the 2023 American Society for Bone and Mineral Research, ASBMR, annual meeting. These results support development of NC605 as a potential highly effective treatment for osteogenesis imperfecta, a rare disease in which bones easily fracture. The number of new bone fractures and bone quality were assessed and compared to control animals and to female OI mice from a prior study. Key findings include: Treatment with the surrogate antibody, NP159 prevented new bone fractures in 90% of male oim compared to 85% of female oim seen earlier. All control mice had one or more new bone fractures. High resolution microCT showed decreased trabecular bone separation with NP159 treatment in both oim males and females. Cortical bone porosity, a measure of mechanical strength of bone, was normal in the treated male mice, in contrast with females who showed increased porosity. There were no changes in the overall bone mineral density for male or female mice. Bone stiffness increased in both male and female oim. Fourier Transform Infrared readouts, a measure of bone quality, in treated females showed a normalization of mineral: matrix ratio, increased acid phosphate and decreased collagen maturity. Interestingly and in contrast, the males showed no similar changes.

08:17 EDT Yatra partners with Welspun World to cater to their domestic travel requirements - Yatra, through its Indian subsidiary, Yatra Online, a corporate travel services provider and online travel company in India, announced a partnership with Welspun World to manage their domestic travel requirements. Through this partnership, Yatra aims to offer tailored, end-to-end travel solutions for Welspun's corporate employees. Yatra will offer its self-booking tool to Welspun designed to serve Welspun's diverse travel requirements.

08:15 EDT Alignment, Walgreens to introduce co-branded Medicare advantage plans - Alignment Healthcare (ALHC) and Walgreens (WBA) have signed an agreement to offer new $0-premium co-branded Medicare Advantage plans in select markets throughout Arizona, California, Florida and Texas starting Jan. 1, 2024, reaching approximately 1.6 million Medicare-eligible adults, pending regulatory approvals. "Walgreens has a rich history of caring for communities, and we are honored to partner with this well-known and trusted retailer and pharmacy to expand access to care for seniors," said Dawn Maroney, president, markets of Alignment Healthcare, and CEO of Alignment Health Plan. "Together, we'll deliver a new level of access - one that makes it easy, convenient and cost-effective for seniors to get the medicine they need and the high-quality service they deserve."

08:14 EDT NKGen Biotech presents interim Phase I trial data at WCN meeting 2023 - NKGen Biotech presented a poster with interim Phase I trial data on the use of its investigational NK cell therapy, SNK01, to treat patients with Alzheimer's disease, AD, at the XXVI World Congress of Neurology, WCN, Annual Meeting in Montreal, QC, Canada and online. The poster, entitled "Use of Expanded Non-Genetically Modified Natural Killer Cells with Enhanced Cytotoxicity in Patient's with Alzheimer's Disease - Interim Report of a Phase I Trial", provided interim results from a single center, open label Phase I trial evaluating the safety, tolerability, and exploratory efficacy of SNK01 in patients with mild cognitive impairment and AD. SNK01 was administered intravenously every three weeks for a total of four treatments using a 3 + 3 dose escalation design in patients. Primary endpoint was safety and secondary endpoints included changes in cognitive assessments and biomarker levels. "The results from our Alzheimer's trial demonstrate that SNK01 has the potential to cross the blood-brain barrier as evidenced by the CSF biomarker data," said Paul Y. Song, CEO of NKGen Biotech. "Furthermore, despite the fact that 2/3rds of enrolled patients in this dose escalation safety trial received what we consider sub-therapeutic doses, SNK01 showed signs of effectively reducing neuroinflammation, a critical factor to effectively treating Alzheimer's. The pressing need for effective Alzheimer's treatments cannot be overstated, and we are committed to addressing this healthcare challenge. We are excited to share additional trial data in Alzheimer's expected later this year as we embark on this new chapter as a publicly traded company."

08:12 EDT TransUnion's TruAudience to integrate with AWS Entity Resolution - TransUnion's marketing solutions business, TruAudience, will integrate its identity product line with AWS Entity Resolution from Amazon Web Services. The integration with the TruAudience Identity product line brings advanced identity resolution capabilities to customers, improving their data hygiene and customer insights while helping to better protect their data by minimizing its movement, as it reads records where they already live.

08:10 EDT INmune Bio presents biomarker, feasability data from Phase 1b study of XPro - INmune Bio highlights some important findings from data presented at the 16th annual Clinical Trial in Alzheimer's Disease to be held October 24-27 in Boston, MA. INmune is enrolling AD patients into a global, blinded, randomized Phase II trial. Summary of CTAD Presentations featuring XPro: P186: Feasibility of the Cumulus electrophysiological neurocognitive platform to enable de-centralized trials in Alzheimer's Disease. In a small group of mild to moderate AD patients, the feasibility of home, self-administered electroencephalogram using the novel system from Cumulus Neuroscience was tested. The study confirmed the feasibility of collecting quality EEG signals at home with strong patient participation and evidence of functional benefit as demonstrated by an acute and chronic boost in P300 amplitude changes after treatment with XPro. P081: Changes in neurology related CSF proteome after treatment with XPro1595 for Alzheimer's disease. Treatment with XPro was associated with dose-dependent improvement in neurology-related proteins that are the most strongly associated with the core AD pathologies of amyloid-beta and phosphorylated tau (pTau), in this sample. These findings provide further evidence that XPro is targeting the neuronal proteins most affected in AD. P055: Changes in cortical microstructure in brain regions associated with cognitive status and disease duration after short-term treatment with XPro1595 for Alzheimer's disease. The poster reports regional improvements in a diffusion MRI measure of cortical grey matter quality after short-term treatment with XPro in grey matter structures that are most affected by AD suggesting that XPro(TM) targets the regions of the brain most affected by AD.

08:08 EDT Fresh Vine submits plan of compliance to NYSE American - Fresh Vine Wine has submitted a plan of compliance to NYSE American addressing how the Company intends to regain compliance with NYSE American's minimum stockholders' equity requirements for continued listing. The Company previously announced that it had received notice from NYSE American that it was not in compliance with the continued listing standard set forth in Section 1003(a)(ii) of the NYSE American Company Guide, which requires a listed company that has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years to maintain at least $4 million of stockholders' equity. The Company reported stockholders' equity of $2.4 million as of June 30, 2023, and has had losses from continuing operations and/or net losses in each of its fiscal years ended December 31, 2020, 2021 and 2022. Pursuant to the Company Guide, NYSE American will evaluate the Company's plan and, within 45 days of receipt of the plan, make a determination as to whether the Company has made reasonable demonstration of an ability to regain compliance with the continued listing standards within the time period prescribed. If the Company's plan is accepted by NYSE American, the Company will have until March 8, 2025 to regain compliance and will be subject to periodic NYSE American reviews, including quarterly monitoring for compliance with the plan. If the plan is not accepted, the Company will be subject to delisting proceedings as specified in the Company Guide. In addition, if the plan is accepted by NYSE American, but the Company is not in compliance with the continued listing standards by compliance deadline, or if the Company does not make progress consistent with the plan, the Company will be subject to delisting proceedings. Fresh Vine Wine previously announced that it has initiated an exploration of strategic opportunities by way of merger, acquisition, or any accretive strategic transaction to enhance stockholder value, which is a focus of its plan of compliance. The Company has engaged The Oak Ridge Financial Services Group, Inc. as its exclusive investment banker to lead the process of sourcing and vetting opportunities, and all inquiries should be directed to Oak Ridge Financial.

08:07 EDT Cellectar Biosciences appoints Yoon, Nanduri as VPs - Cellectar Biosciences (CLRB) announces the appointment of William Yoon, PharmD, MBA/HCM as vice president, VP, medical affairs and Aaditya Nanduri, MS, as vice president, business strategy and analytics ahead of the expected readout of top-line pivotal data for iopofosine I 131 in Waldenstrom's macroglobulinemia in Q4 2023. Prior to joining Cellectar Biosciences, Yoon held the position of Head of Clinical and Value Evidence at Immunogen (IMGN). Nanduri brings a wealth of experience in data and operations, acquired through key roles at organizations such as BeiGene (BGNE), Celgene Corporation, and Ernst & Young.

08:06 EDT FuelCell low-carbon hydrogen product gets IESO Hydrogen Innovation Fund award - FuelCell Energy announced that Ontario's Independent Electricity System Hydrogen Innovation Fund Award has been awarded to a project in which FuelCell Energy is playing a key role alongside Kinectrics and Bruce Power. This fund seeks to establish action-oriented, sector-specific pilot projects with the purpose of evaluating and demonstrating how low-carbon hydrogen technologies can be integrated to strengthen and improve the reliability of Ontario's energy grid. The comprehensive plan submitted by Kinectrics, Bruce Power and FuelCell Energy included performing a techno-economic assessment of hydrogen production as a clean fuel source for heavy-duty vehicles through high-temperature water electrolysis and will explore the use of solid oxide fuel cells for power generation. It will evaluate the economic feasibility, including installation, maintenance and operating costs of hydrogen production, storage, distribution, and power generation infrastructure. This project will seek to demonstrate the value of hydrogen as an integral part of the electrical grid and will identify key environmental, safety, regulatory and operational considerations for its deployment. This project will serve as a pilot for broader deployment at a larger scale including integrating hydrogen systems with nuclear power plants including Small Modular Reactors. The project team will seek to apply the lessons learned in this pilot to future commercial installations of hydrogen electrolyzers and fuel cells.

08:04 EDT electroCore announces extension of gammaCore device listing in NHS Supply Chain - electroCore announced that gammaCore therapy will continue to be listed in the United Kingdom's National Health Service, NHS, Supply Chain catalogue for an additional two years through March 17, 2026. The listing, which commenced on June 4, 2019, was scheduled to terminate on March 18, 2024. "We are delighted the NHS Supply Chain intends to continue to include the gammaCore device within their framework agreement, commencing March 2024 through March 2026 with an option to extend for a further 2 years," stated Mitch DeShon, Vice President of Global Sales & Business Development at electroCore. "Inclusion in this catalogue helps ensure gammaCore therapy is broadly accessible to patients across the UK who may benefit from non-invasive vagus nerve stimulation and adds increased validation to the benefits realized by patients in the UK using gammaCore therapy."

08:04 EDT VirTra launches V-XR training system - VirTra officially launched its pioneering Extended Reality training system, V-XR at the International Association of Chiefs of Police Conference. VirTra has come full circle in its training capability by adding a comprehensive soft skills trainer that transcends boundaries, expanding VirTra's impact beyond traditional law enforcement applications. V-XR powered by VirTra's innovative technology, revolutionizes training by bringing adaptive soft skills training to our traditional law enforcement and military clients as well as private security, hospital security, educational institutions, and criminal justice academies. The V-XR is not a "shoot-don't-shoot" marksmanship trainer. This transformative platform focuses on essential skills such as communication, de-escalation, and the recognition of mental health conditions, including autism spectrum disorders.

08:02 EDT Seelos Therapeutics retains Canaccord Genuity to review potential partnerships - Seelos Therapeutics announced that it has retained Canaccord Genuity to assist in its ongoing review of potential partnerships, collaborations, and similar opportunities.

08:02 EDT Hawe Telekom selects Infinera ICE6 800G solution - Infinera announced that Hawe Telekom selected Infinera's ICE6 800G coherent solution to deliver high-capacity wholesale services to network operators in Poland as well as interconnections to neighboring countries on its Frankfurt-Warsaw-Vilnius route. Hawe Telekom selected Infinera's ICE6 based on the superior economics provided by its industry-leading optical performance as demonstrated during a live network trial from Frankfurt to Warsaw. Leveraging Infinera's ICE6 800G solution, Hawe Telekom will launch its "Super Highspeed Delivery" product, a unique service offering that provides its customers with nx100G services that can be turned up within 48 hours.

07:52 EDT Lockheed Martin reaffirms FY23 segment operating profit view $7.325B-$7.375B - Comments taken from Q3 earnings conference call presentation slides.

07:35 EDT Lockheed Martin backs FY23 cash from operations greater than, equal to $8.15B - Backs FY23 free cash flow view greater than, equal to $6.2B.

07:35 EDT Venus Concept launches new Venus Aesthetic Intelligence branding - Venus Concept announced a company-wide rebranding initiative, introducing Venus Aesthetic Intelligence to reflect its new strategic vision for the company and an enhanced focus on emerging technologies in aesthetics. "It has been a transformational year for the company. With the first phase of our strategic turnaround behind us, we have now set the stage for a fresh new vision for the future of the company. This vision will build upon our leading product innovations, customer focus and align with our long-term strategic growth plan," said Rajiv De Silva, Chief Executive Officer of Venus Concept. The new Venus AI branding represents a forward-looking approach to aesthetics innovation that is core to Venus' future aspirations. The company's product portfolio will continue to evolve and deliver more than just leading device performance - but a shift towards total practice performance; from the moment the patient enters the clinic to the post-treatment recovery.

07:34 EDT ARway.ai launches augmented reality games - ARway.ai announced the availability of stock or custom augmented reality games as spatial experiences in the ARway studio. This strategic expansion is set to further solidify ARway's position as a leading innovator in AR technology as well as indoor spatial mapping.

07:33 EDT Lockheed Martin reports Q3 cash from operations of $2.9B; free cash flow $2.5B

07:33 EDT Lightbridge launches study to assess its fuel for use in CANDU reactors - Lightbridge Corporation announces it has engaged Institutul de Cercetri Nucleare Piteti, a subsidiary of Regia Autonoma Tehnologii pentru Energia Nucleara, RATEN ICN, to perform an engineering study to assess the compatibility and suitability of Lightbridge Fuel for use in CANDU reactors. This assessment will cover key areas including mechanical design, neutronics analysis, and thermal and thermal-hydraulic evaluations. The findings from the engineering study will play an important role in guiding future economic evaluations and navigating potential regulatory licensing-related issues.

07:32 EDT Citizens Bank adopts multiple nCino solutions - nCino announced that Citizens Bank has chosen the nCino Cloud Banking Platform to gain greater flexibility in its internal processes and enhance the services it provides to clients. The bank will implement multiple solutions from nCino including its Commercial Banking Solution, Portfolio Analytics Solution, and Mortgage Suite. This suite of products utilizes a simple sign-on feature to access either a mobile user-interface or a point-of-sale, creating a streamlined workflow with no need for repetitive data entry.

07:28 EDT Goldman Sachs reports Q3 FICC net revenue $3.38B, down 6% y/y - Net revenues in FICC were $3.38 billion, 6% lower than a strong third quarter of 2022, reflecting lower net revenues in FICC intermediation, driven by significantly lower net revenues in currencies and commodities and lower net revenues in credit products, partially offset by significantly higher net revenues in interest rate products and mortgages. Net revenues in FICC financing increased slightly. Net revenues in Global Banking & Markets were $8.01 billion for the third quarter of 2023, 6% higher than the third quarter of 2022. Asset & Wealth Management generated quarterly net revenues of $3.23 billion. Platform Solutions generated quarterly net revenues of $578 million, 53% higher than the amount in the prior year period. Book value per common share increased by 1.5% during the quarter and 3.4% during the first nine months of 2023 to $313.83.

07:16 EDT mdf Commerce enters multi-year agreement with New York counties - mdf commerce announces that Rockland, Chemung, Orange and Ulster Counties in New York State have signed a multi-year agreement for the usage of our source-to-contract solution and our Shop module, a marketplace to easily find and shop from available cooperative contracts. These Counties have been utilizing our sourcing module for over 15 years and, through this agreement, will upgrade their procurement efficiency to include our full source-to-contract technology and innovative shared marketplace.

07:16 EDT Olema Oncology appoints Garland to board of directors - Olema Pharmaceuticals announced the appointment of Scott Garland to the company's Board of Directors. Garland brings more than 30 years of biopharmaceutical industry experience with deep commercial and executive leadership expertise. Garland most recently served as CEO of PACT Pharma, an immuno-oncology company that was focused on developing cell therapies for solid tumors.

07:15 EDT Vigil Neuroscience announces first patient dosed in Phase 1 trial of VG-3927 - Vigil Neuroscience announced that the Company has dosed its first participant in a Phase 1 clinical trial in healthy volunteers evaluating VG-3927, the first and only small molecule TREM2 agonist in the clinic for the potential treatment of Alzheimer's disease, AD. "Dosing the first participant in our Phase 1 trial of VG-3927, the first and only small molecule TREM2 agonist in clinical development for assessment in AD, is an important milestone in our multi-modality strategy to develop novel therapeutics for the treatment of rare and common neurodegenerative diseases," said Ivana Magovevi-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. "With approximately 6.7 million Americans living with AD, there remains a significant need for new therapies with improved safety and efficacy and that can broadly address multiple aspects of AD disease pathophysiology. Our orally bioavailable and highly CNS penetrant TREM2 agonist VG-3927 has a differentiated mechanism of action with multiple potential therapeutic advantages in AD, and we are excited to advance VG-3927 to potentially bring a differentiated treatment option to AD patients." The double-blind, placebo-controlled Phase 1 clinical trial plans to evaluate VG-3927 in SAD and MAD ascending dose cohorts in healthy volunteers. The study is designed to evaluate VG-3927's safety and tolerability, pharmacokinetics, and pharmacodynamics. The Company anticipates reporting interim Phase 1 topline data in mid-2024

07:14 EDT Phoenix Motor, Fermata Energy partner for bus, truck customers - Phoenix Motor and Fermata Energy announced the integration of Vehicle-to-Grid capabilities for all medium-duty electric vehicles manufactured by Phoenix Motorcars. All Phoenix electric school buses, shuttle buses and trucks, from the first-generation vehicles delivered in 2015, to the current generation vehicles can be equipped with V2G capability, enabling fleets to send excess energy back to the grid via Fermata Energy's FE-20 bidirectional chargers. This connection enables DC charging and discharging at the rate of 20kW over the CHAdeMO connection. Older generation vehicles can be enabled with V2G capability via a software update available from the OEM. Phoenix is the first commercial vehicle manufacturer to enable V2G across all vehicles produced. The Company will also equip its next generation vehicles with faster 60kW V2G capability, using the CCS charging protocol in partnership with Fermata Energy. Phoenix and Fermata Energy also announced the signing of a commercial partnership agreement to enable the seamless deployment of V2G capable vehicles, chargers and managed V2G services.

07:12 EDT Gilead to buy 29.9% of Assembly voting stock in $100M pact - Gilead Sciences (GILD) and Assembly Biosciences, Inc. (ASMB) announced that the companies have entered into a 12-year partnership to advance the research and development of novel antiviral therapies, with an initial focus in Assembly Bio's established areas of herpesviruses, hepatitis B virus HBV and hepatitis D virus HDV . Assembly Bio's current portfolio of small molecule antiviral therapeutics includes both clinical and preclinical programs, including next-generation core inhibitor ABI-4334 for the treatment of HBV, long-acting helicase-primase inhibitor ABI-5366 for herpes simplex virus , an orally bioavailable HDV entry inhibitor ABI-6250, and a pan-herpes polymerase inhibitor program...Under the terms of the agreement, Assembly Bio will receive $100M, consisting of an $84.8M upfront payment and a $15.2M equity investment from Gilead. Gilead's initial equity investment at a premium represents 19.9 percent of the outstanding voting stock of Assembly Bio as of the date of closing. In addition, subject to certain conditions, Gilead has agreed to purchase up to 29.9% of Assembly Bio's outstanding voting stock at a premium. ..Following Gilead's exercise of its option for an Assembly Bio program, Assembly Bio will have the right to opt-in to share profits and costs in the United States. For future new programs, Assembly Bio will also have an option to co-promote those products in the United States.

07:10 EDT Bolt Biotherapeutics reports first patient dosed in Phase 1/2 study of BDC-3042 - Bolt Biotherapeutics announced that the first patient has been dosed with BDC-3042 in the single-agent dose-escalation portion of this first-in-human Phase 1/2 clinical study. The study will evaluate BDC-3042 in patients with metastatic or unresectable triple-negative breast cancer, TNBC, colorectal cancer, clear cell renal cell carcinoma, head and neck cancer, non-small cell lung cancer, NSCLC, or ovarian cancer. "We are excited to have dosed the first patient in this first-in-human clinical trial, which will evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of BDC-3042 in a diverse set of advanced cancers," said Edith Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics. "BDC-3042 is a monoclonal antibody that repolarizes tumor-associated macrophages to attack tumor cells and is the first-in-class Dectin-2 agonist. As Dectin-2 gene expression is elevated in TAMs across a broad range of solid tumor types, we see potential for this novel immunotherapy to be used for a wide range of cancers. We are enthusiastic to advance our second innovative immunotherapy program to the clinic with a focus on providing breakthroughs for patients."

07:09 EDT Apellis to present positive Phase 2 NOBLE results of pegcetacoplan - Apellis Pharmaceuticals and Sobi announced that positive results from the Phase 2 NOBLE study investigating pegcetacoplan for the treatment of post-transplant recurrence of primary immune complex membranoproliferative glomerulonephritis, IC-MPGN, and C3 glomerulopathy will be presented at the American Society of Nephrology Kidney Week Annual Meeting. The results showed the potential for a treatment effect in both IC-MPGN and C3G patients treated with pegcetacoplan. At Week 12, of the 10 patients treated with pegcetacoplan: Eight patients showed a reduction in C3c staining by one or more orders of magnitude of intensity from baseline. Five patients showed a reduction in C3c staining by two or more orders of magnitude of intensity from baseline. Four patients showed zero staining intensity, indicating that C3c deposits were cleared. Excessive deposition of C3 breakdown products in the kidney leads to inflammation and damage of the kidney, often causing kidney failure. Additionally, in 12 weeks, treatment with pegcetacoplan showed a mean reduction of proteinuria, which is a key marker of disease progression1, in a subgroup of patients with high baseline levels). Other biomarkers also improved, including an increase in mean serum C3, reduction in mean sC5b-9, and stabilization of kidney function as measured by estimated glomerular filtration rate. There were no discontinuations due to treatment-emergent adverse events.

07:07 EDT Guardforce AI subsidiary secured three-year contract with Japanese retailer - Guardforce AI announced that its subsidiary, Guardforce Cash Solutions Security, has secured a three-year contract with a leading Japanese retailer that was a pre-existing client for its end-to-end cash management solutions, further strengthening the Company's leading position in Thailand. The end-to-end cash management solution in this contract renewal includes Guardforce Digital Machine, Cash-in-Transit, Cash Processing Centre, and Change Fund services across four locations in Bangkok, Thailand. Kee Yun Kwan, Chief Operating Officer of Guardforce AI, stated, "We appreciate our client's support over the few past years. Retail clients are one of our prime customers for our secured logistics solution since retail clients have a relatively large demand for cash processing and require quick and accurate cash counting and trackable digital records. We're the only company in Thailand that provides complete end-to-end cash management solutions, and this contract further strengthens our footprint in Thailand. By maintaining solid relationships with our clients, it allows us to cross-sell additional products such as robotics and other security services."

07:06 EDT DOJ awards Veritone sole-contractor blanket purchase agreement at $15M - Veritone announced it has been selected by the U.S. Department of Justice DOJ for a $15M Blanket Purchase Agreement, allowing all DOJ agencies to easily purchase Veritone software and services. Veritone will provide AI-powered software and professional services to rapidly transcribe, translate, locate, redact and extract critical evidence during early case assessment...This agreement follows the 2021 announcement detailing the expanded availability of aiWARE for all agencies of the DOJ, based on its enterprise-wide ATO or Authority to Operate, from the FedRAMP authorization board for its aiWARE Government platform deployed on both Microsoft Azure Government and AWS GovCloud environments. Historically, the DOJ has been procuring the Veritone solutions through Solutions for Enterprise-Wide Procurement contracts on an agency-by-agency basis. Additionally, the DOJ can leverage Veritone partners, including Deloitte, CACI, PAE, and Leidos, each of which holds a position on the DOJ's $1.5B automated litigation support contract. Veritone's relationships with these key partners provide the DOJ with access to Veritone's world-class AI technology and services for task orders placed under the $1.5 B contract as well.

07:06 EDT Allegro MicroSystems, BMW collaborate on high-efficiency traction inverters - Allegro MicroSystems (ALGM) announced that BMW Group (BMWYY) has selected Allegro as the sole Current Sensor IC supplier for BMW Group's traction inverter systems used across the company's entire fleet of Battery Electric Vehicles. "For more than two decades, Allegro has worked closely with leading automotive customers to develop innovative, high-performance Magnetic Sensors that help increase the power density and improve the efficiency of power electronic systems used in electric vehicles," said Michael Doogue, Allegro's Chief Technology Officer. "We appreciate our strong relationship with the BMW Group, whose innovative mindset, focus on high performance, and technical insights positively influence Allegro's technology and product roadmaps. Our expertise in Hall, TMR, coreless technologies and Automotive Safety Integrity Level rated sensors enables our customers to meet their design targets and accelerate their time to market."

07:04 EDT Monte Rosa Therapeutics announces strategic collaboration with Roche - Monte Rosa Therapeutics (GLUE) announced it has entered into a strategic collaboration and licensing agreement with global healthcare leader Roche (RHHBY) to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. "We are excited to partner with Roche, a leading healthcare and one of the world's top oncology companies. Our QuEEN discovery engine, a highly validated and industry-leading molecular glue degrader platform, has been the cornerstone for Monte Rosa's success, driving the discovery and development of our exquisitely selective MGDs successfully into the clinic. This collaboration will enable and accelerate expansion of our platform into neuroscience and additional areas of oncology. We believe our decision to partner with Roche, a company that shares our vision and drive, will amplify our collective strengths and capabilities to accelerate the development of transformative treatments for patients across several indications," said Markus Warmuth, M.D., CEO of Monte Rosa Therapeutics. Under the terms of the agreement, Monte Rosa Therapeutics will receive an upfront payment of $50M, and is eligible to receive future preclinical, clinical, commercial and sales milestone payments that could exceed $2B, as well as tiered royalties. The parties also agreed on a mechanism to expand the collaboration on multiple targets within the first two years. In that case, additional payments for nomination, preclinical, clinical, commercial and sales milestones are due, as well as tiered royalties on the resulting products.

07:03 EDT Nkarta announces cost containment measures to extend cash runway - Nkarta announced cost containment measures designed to extend its projected cash runway by one year into 2026, funding its operations well beyond the multiple clinical data updates expected in 2024. Nkarta estimates that, as of September 30, 2023, it had cash, cash equivalents, restricted cash, and investments of $278.4 million. This figure is preliminary and subject to completion of Nkarta's financial closing procedures. The decrease in forecasted spend includes a reduction in and re-allocation of headcount combined with a stringent cap on future headcount growth, planned centralization of operations to a single location and early success in the optimization of Nkarta's manufacturing platform. The company expects to announce clinical updates from its three pipeline programs in 2024: NKX101 in the first half of 2024, NKX019 in mid-2024 and NKX019 in 2024. Nkarta will evaluate options to advance each program with additional investment on the basis of those data readouts.

07:02 EDT Nkarta receives FDA clearance of IND application for NKX019 - Nkarta announced the clearance of an Investigational New Drug application by the U.S. Food and Drug Administration to evaluate NKX019, its allogeneic, CD19-directed CAR NK cell therapy candidate, for the treatment of lupus nephritis. The multi-center, open label, dose escalation clinical trial will assess the safety and clinical activity of NKX019 in patients with refractory LN. Patients will receive a three-dose cycle of NKX019 at 1 billion or 1.5 billion cells per dose on Days 0, 7 and 14 following lymphodepletion with single agent cyclophosphamide, an agent with an established safety profile in SLE and LN. The study is designed to enroll up to 12 patients, with the first patient expected to be enrolled in the first half of 2024.

06:53 EDT Bank of America says U.S. consumer spending continuing to slow - The company said, "Our teammates delivered another strong quarter. We generated $7.8 billion in earnings, up 10 percent from the third quarter a year ago. We added clients and accounts across all lines of business. We did this in a healthy but slowing economy that saw US consumer spending still ahead of last year but continuing to slow. Our growth in revenue and earnings allowed us to continue our investments in our people and technology to drive an enhanced client experience."

06:46 EDT Merck receives positive EU CHMP opinion for PREVYMIS - Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of PREVYMIS for prophylaxis of cytomegalovirus disease in adult kidney transplant recipients at high risk. The CHMP has also recommended the approval for extending dosing for PREVYMIS from 100 days to 200 days following transplant in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant who are at risk for late CMV infection and disease. The CHMP's recommendations will now be reviewed by the European Commission for marketing authorization in the European Union and a final decision is expected this year.

06:32 EDT Choice Hotels proposes to acquire Wyndham Hotels & Resorts for $90.00 per share

06:24 EDT Genmab reports Q3 worldwide net sales of DARZALEX $2.499B - Genmab (GMAB) announced that worldwide net trade sales of DARZALEX, including sales of the subcutaneous product, as reported by Johnson & Johnson (JNJ) were $2.499B in the third quarter of 2023. Net trade sales were $1.369B in the U.S. and $1.130B in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.

06:02 EDT Best Buy announces Black Friday deals for everyone start October 30 - Best Buy announced its full lineup of can't-miss holiday shopping dates, beginning with Black Friday Early Access for Members on Oct. 27 and Early Black Friday Deals for Everyone on Oct. 30.

05:55 EDT Peloton expands into Austria - Peloton announced its expansion into Austria, its fifth market outside the US. Beginning immediately, the Peloton Bike, Bike+, and select accessories will be available to purchase in Austria through its expanded relationship with Amazon. Sport-Tiedje, the largest specialist retailer for home fitness equipment in Europe, will sell Peloton Bike, Bike+, Tread, and select accessories.

05:22 EDT Teva announces UNITE study data at World Congress of Neurology - Teva announced that data from the UNITE study presented at the World Congress of Neurology in Montreal, Canada, show that Ajovy reduced migraine attacks and depression symptoms in migraine patients with major depressive disorder. Ajovy is currently approved for the preventive treatment of migraine in adults. UNITE6 is a double-blind, randomized, placebo-controlled, Phase 4 study sponsored by Teva investigating the efficacy, safety, and impact of fremanezumab on patients with migraine and major depressive disorder. Data revealed in an oral presentation by Verena Ramirez Campos, global senior medical director at Teva, showed that patients in the study treated with fremanezumab experienced a significant reduction in Monthly Migraine Days, or MMD, compared to patients on placebo, a reduction in MMD of -5.1 vs -2.9 for fremanezumab vs placebo. Furthermore, a significantly higher number of patients receiving fremanezumab achieved greater than or equal to 50% reduction in MMD compared to placebo during the 12 week double blind period, with a sustained reduction over the longer-term. Two further data sets were presented as posters on the study's secondary endpoints that evaluated the impact of fremanezumab on depression8 and disability. Treatment with fremanezumab resulted in significant reductions in depression symptoms as measured by two commonly used depression rating scores. The mean change at week 12 for fremanezumab and placebo using the Hamilton Rating Scale for Depression was -6.7 vs -5.4 respectively and using the Patient Health Questionnaire-9 score was -7.8 vs -6.3 respectively. Furthermore, fremanezumab demonstrated clinically meaningful improvements in disability outcomes in the study patients with a sustained reduction in their disability over the longer term. The mean change at week 12 for fremanezumab and placebo using the Headache Impact Test score was -8.8 vs -5.2 respectively, and using the Clinical Global Impression-Severity score was -1.1 vs -0.8 respectively. These results indicate that fremanezumab has the potential to reduce the symptoms and cumulative burden of migraine and associated depression.